OOIR: Observatory of International Research

Papers

(The median citation count of Molecular Therapy-Oncolytics is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Lazertinib improves the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 overexpression cancer cells in vitro, in vivo, and ex vivo	199
Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models	152
Ferroptosis gene signature in cholangiocarcinoma	96
esRAGE-expressing oHSV enhances anti-tumor efficacy by inhibition of endothelial cell activation	72
Targeting carcinoembryonic antigen-expressing tumors using a novel transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1	72
Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence	69
Promoting role of pentraxin-3 in esophageal squamous cell carcinoma	61
Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis	54
Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma	52
Synthetic mRNA-based gene therapy for glioblastoma: TRAIL-mRNA synergistically enhances PTEN-mRNA-based therapy	49
Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model	46
A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers	45
Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML	45
Cancer stem/progenitor signatures refine the classification of clear cell renal cell carcinoma with stratified prognosis and decreased immunotherapy efficacy	42
Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity	40
The miR-23a/27a/24-2 cluster promotes postoperative progression of early-stage non-small cell lung cancer	39
Circular RNA circLAMA3 inhibits the proliferation of bladder cancer by directly binding an mRNA	38
PROTACs in gastrointestinal cancers	36
Potential for reversing miR-634-mediated cytoprotective processes to improve efficacy of chemotherapy against oral squamous cell carcinoma	35
In vivo DNA-launched bispecific T cell engager targeting IL-13Rα2 controls tumor growth in an animal model of glioblastoma multiforme	35
CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer	35
Replication-incompetent influenza A viruses armed with IFN-γ effectively mediate immune modulation and tumor destruction in mice harboring lung cancer	34
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy	32
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity	31
Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia	29

Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T	28
The role and application of vesicles in triple-negative breast cancer: Opportunities and challenges	27
Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma	27
CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via m6A modification in hepatocellular carcinoma	27
A library of cancer testis specific T cell receptors for T cell receptor gene therapy	27
Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response	27
Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products	26
Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma	26
Adding recombinant AAVs to the cancer therapeutics mix	26
LINC01296 promotes neuroblastoma tumorigenesis via the NCL-SOX11 regulatory complex	26
Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia	26
A PD1 targeted nano-delivery system based on epigenetic alterations of T cell responses in the treatment of gastric cancer	25
RETRACTED: Comprehensive analysis of FKBP4/NR3C1/TMEM173 signaling pathway in triple-negative breast cancer cell and dendritic cell among tumor microenvironment	25
Nucleic acids and proteins carried by exosomes of different origins as potential biomarkers for gynecologic cancers	25
Radiovirotherapy at twenty	25
Human lung adenocarcinoma CD47 is upregulated by interferon-γ and promotes tumor metastasis	25
Bacterial cancer therapy using the attenuated fowl-adapted Salmonella enterica serovar Gallinarum	25
ScRNA-seq and bulk RNA-seq reveal the characteristics of ferroptosis and establish a risk signature in cholangiocarcinoma	24
Oncolytic adenovirus for treatment of malignant ascites	24
Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade	24
Thank you to our 2021 reviewers	24
Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?	23
The quest for effective immunotherapies against malignant peripheral nerve sheath tumors: Is there hope?	23
Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers	23
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice	23
Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory	23
Seneca Valley virus replicons are packaged in trans and have the capacity to overcome the limitations of viral transgene expression	23
Non-coding RNAs and glioma: Focus on cancer stem cells	23
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells	22
DNA-damaging cancer cells to improve virotherapy	22
Thank you to our 2023 reviewers	22
Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities	22
Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis	22
TTN-AS1 accelerates the growth and migration of nasopharyngeal carcinoma cells via targeting miR-876-5p/NETO2	22
An epitope encoded by uORF of RNF10 elicits a therapeutic anti-tumor immune response	21
Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy	21
A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon	21
Sodium iodide symporter-targeted gene therapy in glioblastoma	21
Redirecting anti-Vaccinia virus T cell immunity for cancer treatment by AAV-mediated delivery of the VV B8R gene	21
Comprehensive landscape of tRNA-derived fragments in lung cancer	20
A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer	20
Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo	20
Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape	20
Therapeutic potential of gene therapy for gastrointestinal diseases: Advancements and future perspectives	19
Oncolytic virus-driven immune remodeling revealed in mouse medulloblastomas at single cell resolution	19
Advancing together and moving forward: Combination gene and cellular immunotherapies	19
Advancements in CRISPR screens for the development of cancer immunotherapy strategies	19
A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering	19
Exploring the potential of eRNAs in cancer immunotherapy	19
Tagmentation-based analysis reveals the clonal behavior of CAR-T cells in association with lentivector integration sites	19

Allogeneic tumor cell-derived extracellular vesicles stimulate CD8 T cell response in colorectal cancer	19
Purple sweet potato delphinidin-3-rutin represses glioma proliferation by inducing miR-20b-5p/Atg7-dependent cytostatic autophagy	19
DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas	19
Targeting mesothelin in cancer	18
Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells	18
A novel chemical attack on Notch-mediated transcription by targeting the NACK ATPase	18
Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project	18
A cancer cell membrane coated, doxorubicin and microRNA co-encapsulated nanoplatform for colorectal cancer theranostics	17
miR-146a inhibits ovarian tumor growth in vivo via targeting immunosuppressive neutrophils and enhancing CD8+ T cell infiltration	17
The complex relationship between integrins and oncolytic herpes Simplex Virus 1 in high-grade glioma therapeutics	17
Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials	17
Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer	17
Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors	17
Non-coding RNAs and glioblastoma: Insight into their roles in metastasis	17
Gaining insights into virotherapy with canine models	17
The next wave of cellular immunotherapies in pancreatic cancer	16
Retraction Notice to: miR-140-3p Inhibits Cutaneous Melanoma Progression by Disrupting AKT/p70S6K and JNK Pathways through ABHD2	16
Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies	16
Icaritin inhibits PLK1 to activate DNA damage response in NK/T cell lymphoma and increases sensitivity to GELOX regime	16
Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma	16
Expanding the landscape of TCR gene therapy targeting MAGE	16
PBX3-activated DLG1-AS1 can promote the proliferation, invasion, and migration of TNBC cells by sponging miR-16-5p	15
Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer	15
Novel roles of METTL1/WDR4 in tumor via m7G methylation	15
Oncolytic viruses: Narcissistic or altruistic arsonists?	14
Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus	14
Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10	14
Exosomal circSHKBP1 participates in non-small cell lung cancer progression through PKM2-mediated glycolysis	14
CRISPR-Cas knockout of miR21 reduces glioma growth	14
PTEN potentiation of oncolytic HSV therapy for glioblastoma	14
LncRNA CBR3-AS1 promotes osteosarcoma progression through the network of miR-140-5p/DDX54-NUCKS1-mTOR signaling pathway	14
Attack of the clones: An NK cell origins story	14
Gene knock-out chain reaction enables high disruption efficiency of HPV18 E6/E7 genes in cervical cancer cells	14
Carboranes as unique pharmacophores in antitumor medicinal chemistry	14
A library of cancer testis specific T cell receptors for T cell receptor gene therapy	14
CD3 engagement as a new strategy for allogeneic “off-the-shelf” T cell therapy	13
Development and comparison of 68Ga/18F/64Cu-labeled nanobody tracers probing Claudin18.2	13
An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition	13
Stabilization of DEPTOR sensitizes hypopharyngeal cancer to radiotherapy via targeting degradation	13
Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors	13
Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition	13
Cardamonin suppresses pro-tumor function of macrophages by decreasing M2 polarization on ovarian cancer cells via mTOR inhibition	13
A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells	13
Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors	13
Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions	13
CD47-targeted optical molecular imaging and near-infrared photoimmunotherapy in the detection and treatment of bladder cancer	12
PI3K-activated MSC proteomes inhibit mammary tumors via Hsp90ab1 and Myh9	12
Dual-targeting vaccine of FGL1/CAIX exhibits potent anti-tumor activity by activating DC-mediated multi-functional CD8 T cell immunity	12
NAD+ depletion enhances reovirus-induced oncolysis in multiple myeloma	12
Combination microRNA-based cellular reprogramming with paclitaxel enhances therapeutic efficacy in a relapsed and multidrug-resistant model of epithelial ovarian cancer	12
Berberine inhibits carcinogenesis through antagonizing the ATX-LPA-LPAR2-p38-leptin axis in a mouse hepatoma model	12
Anti-tumor immunity enhancement by photodynamic therapy with talaporfin sodium and anti-programmed death 1 antibody	12
Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives	12
CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities	11
The tRNA-derived fragment signature in lung cancer	11
A host non-coding RNA, nc886, plays a pro-viral role by promoting virus trafficking to the nucleus	11
Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors	11
Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models	11
PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1	11
Dual EGFR- and TfR-targeted gene transfer for sodium iodide symporter gene therapy of glioblastoma	11
TRIM22 orchestrates the proliferation of GBMs and the benefits of TMZ by coordinating the modification and degradation of RIG-I	11
lncRNA SNHG26 promoted the growth, metastasis, and cisplatin resistance of tongue squamous cell carcinoma through PGK1/Akt/mTOR signal pathway	11
Dynamic fine-tuning of CAR-T cell therapy	11
Oncogenic lncRNA BBOX1-AS1 promotes PHF8-mediated autophagy and elicits sorafenib resistance in hepatocellular carcinoma	11
Next generation oncolytic viruses expressing PADI1 and TIMP2 exhibit anti-tumor activity against melanoma in nude and humanized mouse models	11